Real world evidence: Patients with refractory pemphigus treated with Rituximab

BACKGROUND: Pemphigus is a group of autoimmune blistering diseases, potentially life-threatening. Rituximab received FDA approval in June 2018 for the treatment of moderate to severe pemphigus vulgaris. OBJECTIVES: To evaluate the efficacy and safety of rituximab in patients with pemphigus, resistan...

Descripción completa

Detalles Bibliográficos
Autores principales: Perifani, Vagiani, Dalamaga, Maria, Theodoropoulos, Konstantinos, Theotokoglou, Sofia, Syrmali, Anna, Loumou, Panagiota, Papadavid, Evangelia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8551647/
https://www.ncbi.nlm.nih.gov/pubmed/34746731
http://dx.doi.org/10.1016/j.metop.2021.100142

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8551647/
https://www.ncbi.nlm.nih.gov/pubmed/34746731
http://dx.doi.org/10.1016/j.metop.2021.100142

Ejemplares similares